46 results about "Achalasia" patented technology

The invention provides safe and effective methods for treating and preventing dysphagia, lower esophageal mucosal rings, esophageal strictures, achalasia, gastric mucosal injuries, and bacterial infections. The methods comprise administering at least one proton pump inhibitor, optionally in combination with antibacterial compounds. In one embodiment, the proton pump inhibitor is rabeprazole, a pharmaceutically acceptable salt thereof and/or a stereoisomer thereof.

The invention provides a balloon dilatation device used for treating cricopharyngeal muscle achalasia, which comprises a hollow soft guide pipe with a closed front end, wherein an appropriate positionin the front of the guide pipe is provided with a balloon dilatation section, an appropriate position at the tail part of the guide pipe is connected with a water supply branch, and a water flow passage is arranged in the wall of the guide pipe for connecting and communicating the watering branch and the balloon dilatation section. The balloon dilatation device for treating the cricopharyngeal muscle achalasia has the advantages of simple operation, safety and reliability.

The invention discloses a traditional Chinese medicine formula for the treatment of achalasia of esophagus cardia, which is prepared from wine-fried Chinese sage herb, lotus leaf, radix adenophorae, radix curcumae, burreed tuber, rhizoma zedoariae, aspongopus, amomun fruit, semen dolichoris album, atractylodes rhizome, chuanxiong rhizome, fritillaria and dried orange peel. The formula is decocted into decoction or powder, one dose of the decoction or the powder is taken twice a day in the morning and the evening, and 10 days are taken as a course of treatment. The formula has the effects of promoting blood circulation, removing blood stasis, activating the spleen qi, warming yang, regulating neural muscle and relieving spasm, and can alleviate uncomfortable symptoms of the disease rapidly and effectively control and prevent the occurrence of complications.

The invention relates to an intelligent balloon dilatation therapeutic instrument for cricopharyngeal muscle achalasia, which comprises an instrument body and a physiological saline water tank, a power supply, a main control circuit, a keying panel, a step motor, a peristaltic pump, a water inlet tube, a water outlet tube, a flow sensing transducer, a balloon dilatation catheter and a display screen which are arranged on the instrument body. The balloon dilatation catheter comprises a hollow soft catheter with a closed front end. An appropriate position in the front of the catheter is providedwith a balloon dilatation section, an appropriate position at the tail part of the catheter is connected with a watering branch, and a water flow passage is arranged in the wall of the catheter for connecting and communicating the watering branch and the balloon dilatation section. The intelligent balloon dilatation therapeutic instrument for the cricopharyngeal muscle achalasia is simple in operation, safe and reliable. Simply operated by a doctor, the instrument can fill the balloon with water automatically at a fixed time and a fixed quantity so as to achieve the aim of treating the cricopharyngeal muscle achalasia.

The invention discloses an indwell dilator for treating achalasia of cricophyaryngeus muscles. The indwell dilator comprises an expandable sacculus and a gastric tube, wherein the expandable sacculusis mounted on the gastric tube in a sleeving manner; a first through hole and a second through hole are separately formed in the left side and the right side of the inner side wall of the expandable sacculus; the two through holes are formed in the near end of the gastric tube through an opening of a connecting tube arranged in the gastric tube wall; a pressure monitoring mechanism is mounted above the first through hole; and an injection mechanism is mounted above the second through hole. The indwell dilator for treating the achalasia of cricophyaryngeus muscles disclosed by the invention solves the following problems: in a conventional treatment course of the achalasia of cricophyaryngeus muscles, repeated draw-out and insertion of the gastric tube are required when expansion treatment is carried out by using the expandable sacculus every time, and thus pains and economic expenses of patients are increased; injection of saline water amount required by expansion of the expandable sacculus is evaluated in accordance with feel of a patient and an operator, and therefore, the injection evaluation is not objective, if the saline water amount is injected excessively, esophageal mucosais possibly hurt, otherwise, less amount of saline water is injected, a treatment effect cannot be achieved; and the insertion depth of the expandable tube is difficultly controlled, the pain of the patient is increased if the expandable tube is inserted too deeply, otherwise the treatment effect cannot be achieved if the expandable tube is inserted too shallowly.

The invention provides safe and effective methods for treating and preventing dysphagia, lower esophageal mucosal rings, esophageal strictures, achalasia, gastric mucosal injuries, and bacterial infections. The methods comprise administering at least one proton pump inhibitor, optionally in combination with antibacterial compounds. In one embodiment, the proton pump inhibitor is rabeprazole, a pharmaceutically acceptable salt thereof and/or a stereoisomer thereof.

The invention relates to an intelligent balloon dilatation controlling device for cricopharyngeal muscle achalasia, which is connected with a balloon dilatation catheter for controlling the balloon dilatation, and comprises a device body and a water tank, a power supply, a main control circuit, a keying panel, a step motor, a peristaltic pump, a water inlet tube, a water outlet tube, a flow sensing transducer and a display screen which are arranged on the device body. The intelligent balloon dilatation controlling device for the cricopharyngeal muscle achalasia has the advantages of simple operation, safety and reliability. Simply operated by a doctor, the device can fill the balloon dilatation catheter with water automatically at a fixed time and a fixed quantity so as to achieve the aimof treating the cricopharyngeal muscle achalasia.

The invention discloses a preparation method of a medicine used after the esophageal achalasia operation, aiming to solve the problem of treatment of esophageal achalasia. The medicine is characterized by being prepared from the following active pharmaceutical ingredients by weight: lychee seeds, lindernia ruellioides, glabrous greenbrier rhizome, dried tangerine peel, sensitive joint vetch wood, Chinese starjasmine stem, kudzuvine root, Paris polyphylla Sm., luffa vegetable sponge, catclaw buttercup root, scorched malt and scorched rice sprout. The preparation method comprises the following steps of: (1) extracting essential oil from coarse powder of kudzuvine root, lindernia ruellioides and sensitive joint vetch wood for standby use; (2) grinding the scorched rice sprout into fine powder for standby use; (3) carrying out water extraction and alcohol precipitation on lychee seeds, glabrous greenbrier rhizome, dried tangerine peel, Chinese starjasmine stem, luffa vegetable sponge, Paris polyphylla Sm., catclaw buttercup root and scorched malt and obtaining primary materials after drying the products; and (4) spraying the essential oil into the primary materials, adding the scorched rice sprout fine powder, mixing the materials uniformly, sieving the mixture with a 60-mesh sieve and filling the mixture into a capsule, thus obtaining the medicine. Clinical experiments prove that the medicine has the characteristics of good curative effect and higher safety when being used after the esophageal achalasia operation and deserves clinical application and popularization.

The invention discloses a Lactobacillus rhamnosus NSL0401 with a defecation promoting function and an application thereof. The Lactobacillus rhamnosus NSL0401 is classified and named as Lactobacillus rhamnosus and is preserved in the China Center for Type Culture Collection, the preservation number is CTCC M 2021627, and the nucleotide sequence is as shown in SEQ ID No.1. The Lactobacillus rhamnosus NSL0401 is free of pathogenicity, free of acute toxicity, safe and reliable, and experiments prove that the Lactobacillus rhamnosus NSL0401 can effectively improve defecation parameters of an organism, increase defecation times and the water content of excrement, promote the variety and proliferation of probiotics in the organism and increase the concentration of various short-chain fatty acids, so that the effects of promoting defecation, relieving or treating achalasia constipation are realized, and the intestinal function and health condition of the organism are enhanced.

The invention discloses a method for preparing a drug for treating pediatric esophageal achalasia. The drug is applied to the treatment of pediatric esophageal achalasia. The drug is characterized by being prepared from the following raw pharmaceutical materials in proportioning ratio by weight: fingerleaf rodgersflower rhizome, bombax malabaricum peel, paris polyphylla Sm., luffa cylindrica (L.) Roem., murraya jasminorage, poriacocos (Schw.) Wolf, citrus reticulata Blanco, rtemisia japonica Thunb., trachelospermum jasminoides (Lindl.) Lem., radix puerariae, hordeum vulgare L. and setaria italica Beauv.. The method comprises the following steps of: (1) extracting volatile oil from coarse powder of radix puerariae, bombax malabaricum peel and rtemisia japonica Thunb. for later use; (2) crushing setaria italica (L.) Beauv. into fine powder for later use; (3) carrying out water extraction and alcohol precipitation on fingerleaf rodgersflower rhizome, poriacocos (Schw.) Wolf, citrus reticulata Blanco, trachelospermum jasminoides (Lindl.) Lem., luffa cylindrica (L.) Roem., paris polyphylla Sm., murraya jasminorage and hordeum vulgare L., and drying so as to obtain a preliminary material; and (4) spraying the volatile oil into the preliminary material, adding the fine powder of setaria italica (L.) Beauv., uniformly mixing, sieving by using a 60-mesh sieve, and encapsulating. Proved by clinical trials, the drug prepared by the method has the characteristics of good treatment effect and high safety in the treatment of pediatric esophageal achalasia, so that the method is worthy of clinical application and popularization.

The invention discloses health care product oral liquid for dysphagia and a preparation method of the health care product oral liquid. The health care product oral liquid contains the following raw material medicinal components in parts by weight: 30 parts of dangshen, 15 parts of radix astragali, 15 parts of poria cocos, 5 parts of glycyrrhiza, 15 parts of rhizoma atractylodis macrocephalae, 12 parts of radix polygoni multiflori and 15 parts of fructus ziziphi jujubae. According to the health care product oral liquid for dysphagia and the preparation method of the health care product oral liquid disclosed by the invention, the health care product oral liquid with the effects of invigorating spleen and supplementing qi and alleviating urgent eating is used for esophageal achalasia. Compared with the existing similar products in the market, the health care product oral liquid has the advantages of being smaller in taking dosage, better in taste, higher in bioavailability and efficacy, more stable in quality, simpler in production technology, more convenient to take, faster to absorb and the like.

The invention relates to a traditional Chinese medicine for treating dampness-heat middle energizer type cardia achalasia. The traditional Chinese medicine comprises artemisia eriopoda, craibiodendron stellatum roots, veronica linariifolia, radix curcumae, rhizoma atractylodis, rattletop, Chinese mahonia stems, pawpaw, all-grass or roots of fourangular crotalaria and tuber cubeba. The traditional Chinese medicine can be used for treating the dampness-heat middle energizer type cardia achalasia in clinic.

The invention belongs to the technical field of Chinese herbal medicine preparations, and in particular relates to a traditional Chinese medicine composition for treating achalasia of cardia and esophagus. The composition is prepared from 30 g of radix pseudostellariae, 15 g of rhizoma atractylodis macrocephalae, 15 g of poria cocos sclerotium, 5 g of licorice roots, 15 g of radices paeoniae alba,12 g of lindera aggregata roots, and 15 g of clematidis radix et rhizoma. The composition is added with fructus amomi, rhizoma corydalis or combined with Wubei powder (fine powder of 85% of cuttlefish bone, 15% of fritillaria thunbergii) for patients with belching acid regurgitation, 2-3 g per dose. The composition is added with radices paeoniae alba, fructus aurantii, radix curcumae, or Zuojin pill for patients with liver qi stagnation. The composition is combined with Sanhuang Xiexin decoction for patients with stagnation of liver fire and excessive heat of the stomach. The composition is added with radix astragali, cassia twigs, rhizoma pinelliae or Guifu Lizhong decoction for patients with deficiency cold of spleen and stomach. The composition is added with platycladus orientalis leaves, rhizoma bletillae, donkey hide gelatin, radix notoginseng powder (fried) for patients with hematemesis and bloody stool. The composition is added with ophiopogon roots, caulis dendrobii, radix polygonati officinalis, etc. for patients with deficiency of stomach yin.

The invention provides a traditional Chinese medicine for treating achalasia of cardia caused by deficiency of the spleen and the stomach. The traditional Chinese medicine is prepared from daghestan sweetciorer herb, herb of wilson passionflower, root-bark of Japanese plum, cowpea pod, Indian buead, honeysuckle stem, Chinese taxillus twig, perilla leaf, pericarp of fragrant citrus and manyflower solomonseal rhizome. The traditional Chinese medicine can be clinically used for treating achalasia of cardia caused by deficiency of the spleen and stomach.

The invention discloses a traditional Chinese medicine composition for treating esophageal achalasia caused by phlegm-qi stagnation. The traditional Chinese medicine composition is characterized by being prepared from the following medicinal materials in parts by weight: 5 parts of round cardamom fruits, 10 parts of white perilla stems, 30 parts of ruddle, 30 parts of hydrangea aspera don fruits 10 parts of bergamot, 10 parts of kelp, 10 parts of levant cotton exocarp, 25 parts of rice polishing, 6 parts of grass mass goat stomach, 5 parts of carp louse, 8 parts of oval kumquat leaves, 5 parts of armeniaca mume, 40 parts of ardisia maculosa mez, 25 parts of great willowherb herb, 12 parts of roots of uraria crinit, 20 parts of abelmoschus manilhot, 15 parts of fructus cannabis and 6 parts of liquorice. The traditional Chinese medicine composition is used for treating esophageal achalasia caused by phlegm-qi stagnation and is good in treatment and free of relapse after healing.

Pharmaceutical compositions comprising tricyclic 3,4-propinoperhydropurines and uses thereof for treating wounds, anal fissure, achalasia, disorders of the upper and lower esophageal sphincter, gastroparesis, hypertrophic pyloric stenosis, hemorrhoids, proctalgia fugax, irritable bowel syndrome, muscular spasms, vasospastic disorders, disorders involving uterine, or bladder spasm, sphincter of Oddi dysfunction, and short-segment Hirschprung's are provided. Also provided are methods of treating wounds and muscle disorders by administering the composition of the invention to a muscle or in the vicinity of a muscle either topically or by injection.

The invention discloses a pharmaceutical composition for treating esophageal achalasia. The pharmaceutical composition is applied to the treatment of esophageal achalasia. The pharmaceutical composition is characterized by being prepared from the following raw pharmaceutical materials in proportioning ratio by weight: fingerleaf rodgersflower rhizome, usnea diffracta Vain., poriacocos (Schw.) Wolf, luffa cylindrica (L.) Roem., murraya jasminorage, hordeum vulgare L., setaria italica (L.) Beauv., citrus reticulata Blanco, artemisia japonica Thunb., trachelospermum jasminoides (Lindl.) Lem., radix puerariae and paris polyphylla Sm.. Proved by clinical trials, the pharmaceutical composition has the characteristics of good treatment effect and high safety in the treatment of esophageal achalasia, so that the pharmaceutical composition is worthy of clinical application and popularization.

The invention discloses a method for preparing a postoperative drug for esophageal achalasia. The drug is applied to the treatment of esophageal achalasia. The drug is characterized by being prepared from the following raw pharmaceutical materials in proportioning ratio by weight: litchi chinensis Sonn., lindernia ruellioides (Colsm.) Pennell, poriacocos (Schw.) Wolf, citrus reticulata Blanco, aeschynomene indica L., trachelospermum jasminoides (Lindl.) Lem., radix puerariae, paris polyphylla Sm., luffa cylindrica (L.) Roem., manis pentadactyla Linnaeus, hordeum vulgare L. and setaria italica (L.) Beauv.. The method comprises the following steps of: (1) extracting volatile oil from coarse powder of radix puerariae, lindernia ruellioides (Colsm.) Pennell and aeschynomene indica L. for later use; (2) crushing setaria italica (L.) Beauv. into fine powder for later use; (3) carrying out water extraction and alcohol precipitation on litchi chinensis Sonn., poriacocos (Schw.) Wolf, citrus reticulata Blanco, trachelospermum jasminoides (Lindl.) Lem., luffa cylindrica (L.) Roem., paris polyphylla Sm., manis pentadactyla Linnaeus and hordeum vulgare L., and drying so as to obtain a preliminary material; and (4) spraying the volatile oil into the preliminary material, adding the fine powder of setaria italica (L.) Beauv., uniformly mixing, sieving by using a 60-mesh sieve, and encapsulating. Proved by clinical trials, the drug prepared by the method has the characteristics of good treatment effect and high safety in the postoperative treatment of esophageal achalasia, so that the method is worthy of clinical application and popularization.

The invention relates to an upper esophageal sphincter achalasia segment positioning device and a measurement method. Botulinum toxin injection for treating dysphagia has the advantages of being small in trauma and convenient to operate; and the difficulty lies in accurate positioning of achalasia segment muscle. An existing upper esophageal sphincter achalasia segment measuring device usually adopts upper and lower edge positioning balloons for positioning; but the length of an achalasia segment capable of being measured by the positioning mode is limited; furthermore, the structure is complex; the pipe diameter is relatively large; and a patient feels uncomfortable. According to the upper esophageal sphincter achalasia segment positioning device provided by the invention, a more flexible positioning area is arranged; therefore, the measurable range of the positioning device is relatively large; measurement is more flexible; discomfort of the patient is effectively reduced; and the positioning device has good clinical application value.